ライフサイエンスコーパス: human albumin

1 00 IU in total over 4 days) or a placebo (1% human albumin).

2 cid 2-phosphate and rice-derived recombinant human albumin.

3 nomodulatory molecule from the N terminus of human albumin.

4 no inflammatory signs in any eyes exposed to human albumin.

5 uction of human alpha-feto-protein (AFP) and human albumin.

6 ity copper-binding site of the N-terminus of human albumin.

7 hosphate (DFP), and sarin covalently bind to human albumin.

8 to achieve affinity capture of lysozyme and human albumin.

9 Control animals received human albumin.

10 h preserved structural features had taken up human albumin.

11 ved, with BSA binding close to twice that of human albumin.

12 Animals were treated with either 25% human albumin, 1.25 g/kg, or saline vehicle i.v. at 90 m

13 Human albumin (25%, 2.5 mg/kg; n=12) or vehicle (0.9% sa

14 tated Ringer's solution, dextran, hespan, 5% human albumin, 25% human albumin, 3.5% hypertonic saline

15 tion, dextran, hespan, 5% human albumin, 25% human albumin, 3.5% hypertonic saline, and 7.5% hyperton

16 Human albumin (5%) was used as the main replacement flui

17 Treatment with human albumin administered intravenously in the immediat

18 Human albumin (Alb), present at various levels throughou

19 , HepG2, or Chinese hamster ovary cells with human albumin (ALB)/human apoB chimeric cDNA constructs:

20 oGen) with that of active control (sonicated human albumin [Albunex]) for left ventricular (LV) cavit

21 Human albumin, alpha(1) -antitrypsin, glypican-3, alpha-

22 Notably, upon transplantation, human albumin and alpha1-antitrypsin (A1AT) in mouse ser

23 hepatocytes contained significant amounts of human albumin and alpha1-antitrypsin.

24 Incubations of alachlor (0-1000 microM) with human albumin and bovine serum albumin (BSA) resulted in

25 Humanized liver rats expressed human albumin and complement proteins in serum and showe

26 tion sites (12 lysines and 2 asparagines) on human albumin and highlight reaction specificity for the

27 sing concentrations of human proteins (e.g., human albumin and human C3a) can be measured in the bloo

28 g, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with c

29 ps of 5 each to receive 2 different doses of human albumin and nonhuman nucleic acids and their respe

30 nd of His-Halo-Sumo or amino-terminal end of human albumin and purified from the cell culture medium.

31 e macrocycle with a significant affinity for human albumin and substantial in vivo circulation half-l

32 Isovolemia was maintained with 5% human albumin and/or autologous plasma.

33 oses of 50 units/kg every 12 hrs, or 5 mg/kg human albumin as placebo.

34 er a single infusion of CDP571 (5 mg/kg), or human albumin as placebo.

35 Presence of human albumin at physiologic concentration in the cultur

36 sticides and nerve agents bind covalently to human albumin at Tyr411.

37 ciated with an antibody response against the human albumin-based carrier protein, which was prevented

38 We now extend these studies to show that human albumin, but not ceruloplasmin, mediates the conve

39 The interfacial unfolding induced in human albumin by hyaluronic acid facilitates in vitro li

40 We have engineered human albumin by introducing single point mutations in t

41 In animals treated with human albumin, cortical neurons with preserved structura

42 l, a nanoparticle conjugate of paclitaxel to human albumin, exhibits efficacy in pancreatic cancer, n

43 Colonies of cytokeratin-18 and human albumin-expressing cells were present in the liver

44 Human albumin expression was detected only in CCl(4)-tre

45 Additionally, we find that human albumin follows a domain associated unfolding path

46 Thus, the affinity of human albumin for bilirubin is not constant, but varies

47 onstrates that DDFP is superior to sonicated human albumin for LV cavity opacification, endocardial b

48 was used to study the reaction of CBDP with human albumin, free tyrosine, and human butyrylcholinest

49 with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on traum

50 s, lactobacilli, Mycoplasma hominis, and the human albumin gene (for quality control).

51 composed of IFN-alpha2b genetically fused to human albumin, has an extended half-life and early evide

52 e albumin group was administered 25 g of 25% human albumin in 0.9% saline every 8 hrs for a total of

53 Vapor phase TDI was found to react with human albumin in a dose-dependent manner, with up to 18

54 Further immunohistochemistry of human albumin in retrieved cell aggregates confirmed the

55 subgroups of mice were resuscitated with 4% human albumin in the absence or presence of vehicle, val

56 The transplanted hiPSC-EB-HLCs secreted human albumin into the host plasma throughout the examin

57 Human albumin is thought to hydrolyze esters because mul

58 ells with human-specific gene expression and human albumin levels in murine serum that were higher fo

59 ing technetium 99m ((99m)Tc) macroaggregated human albumin (MAA) SPECT/CT.

60 thod was evaluated with data from technetium human albumin macroaggregates ((99m)Tc-MAA) evaluations

61 Human albumin made a covalent bond with CBDP, adding a m

62 pper-62-PTSM congeners with less avidity for human albumin may prove more suitable for evaluation of

63 Treatment with human albumin may provide direct neuronal protection.

64 We hypothesized that sonicated 5% human albumin microbubbles (Albunex) adhere to disrupted

65 Human albumin or plasma was treated with organophosphoru

66 perfusion: Hextend (hetastarch solution); 5% human albumin; or lactated Ringer's solution.

67 of albumins and hyaluronic acid reveals that human albumin presents limited conformational changes up

68 Both bovine and human albumin prevented T/HS lymph-induced HUVEC cytotox

69 Intracameral injection of human albumin protein did not cause ocular inflammation.

70 - 22, and 467 +/- 47 nm for rat, rabbit, and human albumin, respectively.

71 n ratio potential by engineering recombinant human albumin (rHSA) variants with varying hFcRn affinit

72 ein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate

73 e magnitude of injury in T/HS rats receiving human albumin (shed blood + 0.12, 0.24, or 0.36 g/kg) or

74 mary fluid for sepsis resuscitation, with 5% human albumin solution (HAS) as the second line.

75 on to the ischemic area of human PRP lysate, human albumin solution (HSA), saline or no treatment at

76 major outcomes, short-term administration of human albumin solution appears to be more effective than

77 The use of 25% human albumin solution could also effectively manage asc

78 omly assigned to receive either targeted 20% human albumin solution for up to 14 days or until discha

79 Taken together, human albumin solution infusions may be used to reduce c

80 Human albumin solution is a commonly used therapeutic ag

81 In vivo administration of human albumin solution to these patients significantly i

82 solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24

83 by 2 mg/kg over 24 h) or placebo (0.2 mg/mL human albumin solution) in addition to conventional medi

84 atients with repeated daily infusions of 20% human albumin solution, as compared with standard care,

85 and nononcotic properties, administration of human albumin solutions (HAS) have been found to be bene

86 the lack of evidence for the superiority of human albumin solutions compared with crystalloids in im

87 sively review the indications for the use of human albumin solutions, examine the associated risks, a

88 e computed at technetium 99m macroaggregated human albumin SPECT/CT was associated with better overal

89 osemicarbazone), interact more strongly with human albumin than dog albumin.

90 thelial and biliary duct cells, and secreted human albumin that was detected in circulation.

91 Human albumin therapy within the first 4 h is highly neu

92 orm takes advantage of the long half-life of human albumin to provide a new treatment approach that a

93 gree of IgG extravasation was not changed by human-albumin treatment.

94 ble-blind, controlled study in which 25 g of human albumin vs. placebo was administered intravenously

95 ssure following a fixed intravenous bolus of human albumin was analyzed, first before start of, and t

96 The binding of DFP to Tyr411 of human albumin was confirmed by electrospray tandem mass

97 rotein were expressed in the mouse liver and human albumin was detected in the serum of mice that had

98 xidation of A1-1 was modest and oxidation of human albumin was extensive in the presence of HYP, as m

99 Human albumin was not expressed in the starting stem cel

100 The increase with 5% human albumin was only 2.2 x baseline, and 25% albumin d

101 Fatty acid-free human albumin was treated with 0.5 mm p-nitrophenyl acet

102 globulins (IgG), rat albumin and (exogenous) human albumin was used to study blood-brain barrier chan

103 We exposed podocytes to recombinant human albumin, which lacks lipids and proteins that bind